Oura’s IPO Is on Hold. What Does It Tell Us About the Business?
Oura’s delayed listing puts the proposed deal in focus: who would have received the cash, and whether ring sales and membership can produce the earnings its valuation requires.
N
Neverlater
15 October 2026
In this article
Oura Ring 4 in silver, based on its official product reference, in an imagined daily commute. Photographic editorial illustration; no actual wearer, transit location, medical result or listing event is depicted.
On 29 September, Oura postponed its announced Nasdaq offering, citing uncertainty in the IPO market despite what it described as strong demand. The company reported 5.7 million paid members and forecast 90% revenue growth for fiscal 2026, which ended the next day. It gave no replacement date. Those are company statements; neither strong demand nor a delay tells us what price investors would ultimately accept. [1]
The ring is still Oura’s largest source of revenue. In the nine months to June 2026, hardware supplied 80.2% of sales and membership 19.8%. Membership grew faster and supplied roughly 32% of gross profit, by our calculation from the filing. Oura’s economics depend on both selling devices and retaining paid relationships; the filing does not establish separate operating profit for either stream.
Go deeper
What does this mean for your business?
Discuss this article privately with Neverlater. Its title and link stay attached, so you can start with the question that matters to you.
postponement defers the offering’s liquidity and additional borrowing benefits, but does not establish that weak unit economics caused the pause. The ring and membership must still be judged together: acquisition, product development and servicing all have to be paid for. Recently, growth in operating expenses has absorbed almost all the additional gross profit.
Oura financial and product sources rechecked 11 October 2026. Historical accounts run through 30 June 2026; the September growth update remains a forecast, not a published result for the full year. The Samsung Indonesia comparison was added and checked on 12 October. Dollar figures are US dollars. Calculations and judgments are identified separately.
1. Compare the ring with the recurring relationship
Neverlater comparison from Oura’s S-1/A, pages 102 to 104, for the nine months to June in each year. Membership includes extended warranties. Revenue mix and growth do not establish separate operating profit; membership gross profit below is an estimate using a rounded disclosed margin.
In the comparable nine months to June, hardware revenue rose from $588.7 million in 2025 to $974.0 million in 2026; membership rose from $108.8 million to $240.5 million. The filing reports growth of 65% and 121%, respectively. Membership’s calculated share of revenue rose from 15.6% to 19.8%, while hardware’s fell from 84.4% to 80.2%. [3]
The faster growth rate belongs to membership, but the larger increase in dollars still came from hardware: $385.3 million against $131.7 million. Hardware supplied almost three quarters of the added revenue. The ring is doing more than opening the door to a future service business; selling it remains the main source of revenue and growth in dollars today.
Gross profit gives membership more weight. Against total gross profit of $662.2 million, its $240.5 million of revenue at a disclosed, rounded 89% gross margin implies about $214 million, or 32% of the total. On that approximation, hardware supplies the remaining roughly $448 million, or 68%. These are our estimates using the rounded membership margin, not disclosed operating profit for either stream. Membership revenue includes extended warranties, so it should not be relabelled pure subscription ARR. [3]
The ring is how a customer enters that relationship. The screenless ring can be selected as jewellery and worn overnight. Ring 5 launched with six finishes and US starting prices of $399 for base finishes and $499 for premium finishes. These are launch prices, not a current delivered quote for Indonesia. [5]
US membership is $5.99 a month or $69.99 a year, with one included month for new members and applicable taxes extra. Without membership, the ring still works, but app insights are much more limited; three daily scores and personal data export remain. The customer therefore buys both an object and a decision about continuing to pay. [6]
The recurring service earns its place when someone uses a trend to change an evening routine, interpret recovery or ask a better question. It becomes vulnerable when it feels chiefly like a toll on information the customer thought the hardware price had already bought. Price alone cannot establish which experience dominates.
The filing reports approximately 85% weighted average retention over twelve months at June 2026. That includes subscribers who left and returned within the measurement window. It is evidence of persistence, with a defined scope, rather than a count of uninterrupted subscriptions or proven health improvements. We would want to know what it costs to preserve that retention. [3]
Retention makes the recurring relationship worth examining, but it does not allocate the cost of keeping it. Collected paid months must help cover acquisition, delivery, service and replacements. Comparing equally mature customer groups would help establish how much those relationships contribute after costs. The public figures do not disclose those cohort economics or a separate operating result for membership.
2. Count what the combined business keeps
Neverlater calculation from Oura’s S-1/A, pages 102 to 105. The bars allocate the increase in gross profit across expense increases and additional operating profit. These are changes between comparable nine month periods, not total spending or a forecast.
The consolidated accounts supply the next test. Even a membership stream with a high margin can coexist with heavy spending to acquire customers, develop the next ring and run the company. The table shows what the combination retained after operating expenses.
US$ millions, except margins
Nine months to June 2025
Nine months to June 2026
Revenue
697.6
1,214.5
Gross profit
356.0
662.2
Operating expenses
295.8
591.0
Operating profit
60.3
71.2
Operating margin, calculated
8.6%
5.9%
Source: S-1/A, MD&A pp. 102 to 106. Calculated 2026 operating margin is $71.188m ÷ $1,214.506m = 5.9%; the filing’s percentage table displays 7%. We use the dollar statements before rounding.
The improvement in gross margin is real. Calculated from the rounded dollar amounts in the table, gross margin rose from 51.0% to 54.5%. Operating expenses, however, rose from 42.4% to 48.7% of revenue. Percentages are rounded independently. Oura earned more gross profit per sales dollar while spending an even larger share below that line. That is how a stronger gross margin can coexist with a lower operating margin.
Of $306.1 million in additional gross profit, $295.2 million was absorbed by additional operating expenses. Only $10.9 million reached operating profit. In other words, about 96% of the improvement in gross profit was spent below that line. Revenue rose 74%; operating profit rose 18%. This is the central tension in the model today.
The latest quarter is weaker than the total for nine months suggests. In the three months to June, $408.7 million of revenue produced $243.7 million of gross profit and $248.6 million of operating expenses. The operating result was a $5.0 million loss, compared with an $8.8 million profit a year earlier. Calculated operating margin moved from positive 3.8% to negative 1.2%. [3]
The expense bridge makes the counterargument more concrete. Sales and marketing rose $117.6 million, research and development $105.7 million, and general and administrative spending $71.9 million. Oura attributes $72.8 million of the marketing increase to paid media and advertising, including Ring 5 launch activity; $52.1 million of the research increase to personnel; and $48.3 million of the administration increase to professional fees, including intellectual property litigation and preparation for being public. [3]
The spending mixes future product investment with the cost of reaching and serving today’s customers. The filing does not establish that it all disappears after launch. Better warranty rates and unit manufacturing costs deserve credit, but do not settle whether these larger operating expenses will scale.
3. Ask partnerships to improve the relationship
An imagined conversation about a wearable. Editorial illustration using an Oura Ring 4 Silver reference. Oura Ring is not a medical device; no diagnosis, treatment or actual clinical deployment is depicted.
Oura’s Dexcom integration lets eligible users view data from a separate Stelo glucose biosensor alongside their Oura information. The support page limits this feature to the US. The ring itself does not measure glucose. The opportunity is to make information more useful by bringing complementary services together. [8]
Its June announcement with Counsel Health began a rollout to eligible members in 43 US states. Automated medical chat was included in membership, while physician care could cost extra. Counsel’s licensed physicians provide that care. Oura states that the ring and Advisor are not medical devices. [9]
The disclosed rollout boundaries matter to any growth case; neither establishes access in Indonesia. The financial question is whether greater use or retention pays for the partner services. Responsibility for care, consent and the risks of anxiety or misplaced reassurance also remain relevant. Specific health claims need evidence for the intended use and population.
We would give these integrations no separate profit contribution in a valuation case until commercial terms or observable economics support one. That is a modelling choice, not a claim that they are worthless. Evidence of greater retention or spending after partner costs would justify revisiting it. A growing partner list, by itself, would not.
4. Follow the money in the proposed offering
Offering economics belong in the financial record. Editorial illustration of an imagined working desk, using an official Oura Ring 4 Silver product reference; no actual financial documents or IPO event are depicted.
Of the 50 million shares offered at an indicated $40 to $44, Oura would sell 13.5 million. Existing shareholders would sell 36.5 million. At the $42 midpoint, $2.1 billion of gross proceeds would split into $567 million for the company and $1.533 billion for selling holders, before fees. Secondary sales account for 73% of the base offering. [3]
The amount left for the business is smaller still. The prospectus estimated company net proceeds of $532.6 million, with $526.4 million intended for tax withholding when employee restricted stock units settle. Roughly $6.2 million remained under those midpoint assumptions. The withholding obligation was tied to the IPO settlement; postponement did not leave the same bill immediately due without its funding.
The proposed transaction would have provided employee and shareholder liquidity, access to a public market and additional borrowing capacity. The pause delays those benefits. A headline about a $2.2 billion IPO is a poor guide to the new cash available for product development. Most proceeds already had another destination.
Capital allocation deserves a separate judgment from product quality. In the nine months to June, Oura spent $1.173 billion repurchasing common and preferred shares. Its $924.3 million loss attributable to common shareholders reconciles $60.8 million of net income with a $985.0 million deemed preferred dividend associated with repurchases. Calling that an operating loss would be wrong. Ignoring the cash spent to provide liquidity would be wrong too. [3]
5. Test the earnings behind the proposed price
Extra time can produce better evidence about devices and customer behaviour. Editorial illustration using an Oura Ring 4 Silver reference; not an Oura research facility or observed study.
The earnings case also needs a cash check. Oura generated $328.0 million of operating cash in the nine months to June, and its October 2025 funding announcement reported more than $900 million raised. Neither number is the present cash balance. June cash was $371.8 million against $380.1 million of debt; an August revolver repayment changed that position again. [3][10]
The cash bridge also matters. Of the $328.0 million of operating inflow, $60.8 million came from net income, $28.3 million from noncash and other reconciliation adjustments, and $238.9 million from changes in operating balances. Inventory releases and increases in liabilities, deferred revenue and deposits supplied cash; receivables and prepaid balances consumed it. Those movements cannot be extended mechanically as recurring earnings. The cash is real, but some comes with work still to perform or obligations still to settle. [3]
Completing the IPO would have unlocked another $245 million of commitments for revolving credit, subject to related conditions. Waiting preserves the choice of transaction timing while postponing that flexibility and shareholder liquidity. The company’s stated reason for postponement does not reveal the investor order book or management’s minimum acceptable price.
At $42 and the proposed 320,945,459 shares after the offering, basic equity value would have been $13.48 billion. This excludes further option and award dilution and was never a completed market price. Rather than borrowing a flattering multiple from another category, ask what earnings would sit beneath that number.
An illustrative earnings test over three years. Start with $1.725 billion of revenue, calculated as FY2025 revenue of $907.856 million multiplied by the company’s forecast 1.90 growth factor for FY2026. Then apply the chosen growth rates and net margins below for three further years. These are sensitivities, not our forecast or probabilities.
Chosen annual growth / net margin in year three
Sales in year three
Net income in year three
Unchanged $13.48bn value / that income
10% / 5%
$2.30bn
$115m
117×
20% / 10%
$2.98bn
$298m
45×
30% / 15%
$3.79bn
$568m
24×
Formula: revenue anchor × (1 + chosen growth rate)³ × chosen net margin. Divide the proposed basic equity value by that income. No discount to present value, return on the share price, future dilution or target multiple is calculated. The forecast revenue anchor is not a reported FY2026 result.
The exercise makes the dependence visible. Revenue growth alone leaves a substantial earnings burden. Even the middle case assumes three further years of growth and a net margin twice the roughly 5% recorded in the first nine months. The strongest case requires much better profitability, not merely more members. Describing it as a health platform cannot substitute for those assumptions.
Hold growth fixed to isolate the margin assumption. At 20% annual growth for three years, the same revenue anchor produces $2.981 billion of sales in year three. Net margins of 5%, 10% and 15% would then produce about $149 million, $298 million and $447 million of net income, respectively. The unchanged proposed basic equity value would equal roughly 90×, 45× and 30× those earnings. Each five percentage point change in net margin moves annual earnings by about $149 million at that fixed revenue. This is an additional sensitivity, not a forecast; the same exclusions concerning discounting, dilution, returns and target multiples apply.
6. Judge the relationship in the next accounts
The lasting question is what a customer relationship produces after acquisition and service costs. Editorial illustration of an imagined decision using an Oura Ring 4 Silver reference; no supported local payment feature or measured outcome is depicted.
The business case remains open while the offering is on hold. The latest disclosed quarter ended with operating expenses above gross profit. The next accounts can show whether the larger recurring relationship improves that result:
Operating conversion. The June quarter baseline is a $5.0m operating loss and negative 1.2% margin. If the IPO resumes, the prospectus anticipates about $160.0m of compensation expense connected with settling restricted stock units. Show that charge separately alongside the reported result; ongoing compensation and dilution still count. On a comparable basis, a return to operating profit with expenses growing more slowly than gross profit would support the investment explanation. Deterioration despite membership growth would weaken it. [3]
Cost of keeping members. The disclosed retention baseline over twelve months is about 85%, including returning members. Stable retention accompanied by better device servicing economics would strengthen the recurring case. A weaker rate on the same definition, or renewed warranty pressure without compensating economics, would weaken it. Missing disclosure of cohort costs remains an unknown, not a failure proved.
Capital left to build. Reconcile future cash generation, replacements, investment and owner liquidity separately. We would reconsider the valuation only with updated terms and evidence of earnings improvement. A renewed filing date or a larger headline transaction would not satisfy that test.
The postponed offering was largely a liquidity event; it would have left little new cash for building the business. The ring and membership still form one commercial relationship, with different margins and obligations. The filing demonstrates substantial membership gross profit; it does not establish membership operating profit after allocated costs. Our conviction would grow if that relationship produced better consolidated earnings while preserving retention and funding the service still owed. The pause has not answered that earnings question, and a new listing date alone would not answer it either.
Buyer sidebar: availability in Indonesia
Oura’s page of supported countries, updated 7 October, does not list Indonesia. Membership activation requires a supported country; payment methods from unsupported countries are not accepted, and use outside listed regions may void warranty coverage. An importer’s stock does not establish service eligibility. Obtain Oura’s confirmation for your actual residence and billing situation before paying. [13]
Samsung’s November 2024 Indonesian Galaxy Ring launch described insights included without charge through Samsung Health. That is a different service bundle, not proof of equal measurement quality, current stock, superior value or permanent future pricing. Its Indonesian product page specifies Android 11 or later, at least 1.5 GB of memory, the required apps and a Samsung account. Some functions need a Samsung Galaxy device; availability varies by region. [14] [15]
Compare only services supported for your country, billing method and phone. Count hardware, required membership, delivery, taxes and any necessary accessory or phone change in the first year bill, then confirm the return and repair route and its cost. These are purchase conditions; they do not establish Oura’s investment value.
Reference bank
Oura financial and product sources rechecked 11 October 2026 UTC. The Samsung comparison below was added and checked 12 October. Contextual Reuters reporting was retained from the 9 October review. Financial periods, company forecasts and Neverlater sensitivities are separate.
1. Oura Postpones Initial Public Offering Company announcement, 29 September 2026. Confirms postponement, management’s stated reason, update on paid members and growth forecast for the fiscal year. Forecast and demand statements are company claims; no replacement date stated.
2. Oura Announces Launch of Initial Public Offering Company announcement, 21 September 2026. Primary and secondary shares, indicated price range and proposed listing. Describes a planned transaction, not completed proceeds. Article arithmetic excludes the underwriters’ option to buy additional shares.
3. Oura Form S-1 Amendment 1 Filed 21 September 2026. Rechecked 11 October. Glossary p v; use of proceeds p83; IPO settlement compensation in capitalization p85; operating results for nine months pp102 to 106, including hardware and membership revenue on p103 rechecked 12 October; quarterly dollar statements pp109 to 110; liquidity pp113 to 115; cash flow statement F-48; repurchase accounting Note12 F-66. Fiscal years end 30 September. Calculated operating margins use dollar figures, which reconcile. Estimate of membership gross profit uses a rounded margin. New calculations are explained beside the relevant tables.
4. Reuters on the IPO filing 3 September 2026, Reuters via Investing.com. Original reporting independently checks the revenue, growth and net income figures for the nine months.
5. Oura Ring 5 launch Company announcement, 28 May 2026. Product form, finish and evidence of US prices at launch. Hardware prices are launch MSRPs, not a current delivered purchase quote. Product performance statements remain issuer claims.
6. Oura Membership support Official support page checked 11 October 2026 UTC. US membership prices, introductory month and availability by region. No tax or checkout total for a specific customer established.
7. Oura Membership product page Official page checked 11 October 2026 UTC. Explains reduced functionality without membership. Product design evidence, not independent evidence of customer satisfaction.
8. Oura glucose tracking support Official support page updated 7 October 2026, checked 11 October UTC. Identifies the separate Stelo biosensor and app integration. Does not establish glucose sensing by the ring.
9. Oura and Counsel Health integration Company announcement, 8 June 2026. Initial rollout scope, optional participation, care provider, additional physician costs and limitations concerning medical devices. Does not disclose partnership profitability or prove health outcomes.
10. Oura Series E funding announcement 14 October 2025. Historical funding amount and approximate private valuation. Neither establishes present cash, current equity value or pricing in public markets.
11. Reuters on the postponement 29 September 2026, Reuters via Investing.com. Market context and reporting around the stopped transaction. The article does not treat reported demand indications as independently verified orders.
12. Official product illustration references Product imagery submitted by Oura in the prospectus was inspected before creating the illustrations. Five article illustrations are editorial interpretations, not Oura advertising, photographs or endorsement. The hardware and membership graphic uses the p103 revenue comparison. The operating expense chart is a calculation from the filing, with the period and inputs specified.
[13. Supported countries] Official Oura support page updated 7 October 2026; rechecked 11 October. Indonesia is absent from the listed shipping and retail regions. The page states membership activation/payment restrictions and possible warranty consequences. This does not adjudicate an individual customer’s existing overseas membership.
14. Samsung Indonesia Galaxy Ring launch 7 November 2024 announcement, checked 12 October 2026. Evidence of the official local launch and the stated inclusion of insights through Samsung Health. Historical launch terms do not establish current delivered price, stock or permanent future pricing.
15. Samsung Indonesia Galaxy Ring specifications and footnotes Checked 12 October 2026. Footnotes 7, 23 and 28 specify phone and app requirements and functions requiring Samsung Galaxy devices. Regional limitations remain. No comparison of sensing accuracy or health outcomes was performed.
Calculation notes. Historical inputs use filing values in thousands before rounding. Added gross profit of $306.142m equals $117.585m additional sales and marketing, $105.722m research and development, $71.912m general and administrative expenses, and $10.923m additional operating profit. The earnings test over three years is a sensitivity on company forecast revenue and a proposed basic equity value, with no target price. The added historical ratios divide the rounded table amounts by the revenue for the same period. The sensitivity with growth held fixed uses $907.856m × 1.90 × 1.20³ = $2,980.6728192m of sales, then applies 5%, 10% or 15% net margin; the numerator for equity value is $42 × 320,945,459 shares = $13,479,709,278. No Indonesian customer behaviour, cohort costs or comparative health outcomes are estimated. Revenue shares and changes use the unrounded p103 inputs in US$ thousands: hardware 588,726 to 973,980; membership 108,843 to 240,526; total 697,569 to 1,214,506. Membership gross profit is estimated as $240.526m × 89% = $214.06814m; the hardware residual is $662.167m − $214.06814m = $448.09886m. Both estimates inherit the rounding of the disclosed membership margin and do not allocate operating costs.
This is analysis of the business model, not an investment recommendation or medical advice. Cohort costs, partnership profitability and future IPO timing remain unverified.
What assumptions or evidence should I examine before acting on this article?
A human response, usually within 1-2 business days, not an instant AI answer. Questions remain editable until you press Send. You will be asked to sign in if needed.
No approved comments yet. Be the first to add a thoughtful note.
Discussion
Loading discussion...